Indication

In combination with rituximab for the treatment of adult patients with Waldenström's macroglobulinaemia.

Medicine details

Medicine name:
ibrutinib (Imbruvica)
SMC ID:
SMC2259
Pharmaceutical company
Janssen-Cilag Ltd
Submission type
Full
Publication due date:
12 October 2020
SMC meeting date:
01 September 2020
Patient group submission deadline:
06 July 2020